Live Feeds
● LIVE Updated 11d ago · 13 sources tracked

Silicon Valley's longevity drug obsession is facing its first real reality check

The pursuit of longevity drugs in Silicon Valley is meeting significant skepticism as experts question the actual efficacy of current methods. Critics argue that misinformation and hype threaten the credibility of longevity science. Some researchers are now shifting focus from lifespan to biological resilience.

RSS Source map (11)

What changed

New reports indicate a growing tension between longevity hype and scientific evidence.

Live updates

  1. Silicon Valley Longevity Obsession Faces Reality Check

    The pursuit of longevity drugs in Silicon Valley is meeting significant skepticism as experts question the actual efficacy of current methods. Critics argue that misinformation and hype threaten the credibility of longevity science. Some researchers are now shifting focus from lifespan to biological resilience.

    Still unconfirmed:

    • Isomorphic Labs raised $1.2 billion in a Series B round for AI drug discovery.
    • Bryan Johnson used a transplant drug to attempt to live longer.
    • Some experts suggest using organ-specific and trajectory-based biomarkers instead of a single consumer number.
    • Misinformation and false promises may be the greatest challenge facing longevity science.
    • There is currently a lack of consensus on which longevity interventions actually work.
    confidence 70%